Any current/future new fundraising through debt or equity?

The transcript does not mention any current or planned fundraising through debt or equity. The company has a strong cash surplus of INR1,520 crores, including INR950 crores received as part payment for a European contract. They also have an overdraft (OD) facility on fixed deposits, indicating access to short-term credit if needed. Management appears focused on using available cash and possibly M&A opportunities without immediate plans for additional fundraising. The emphasis is on investing in capex for growth (INR300 crore planned for FY26) funded largely from internal resources. No explicit

Any current/future capex/capital investment/strategic investment?

FY '26 capex is estimated around INR 300 crores, split between maintenance and growth capex. Growth capex includes investments in Jammu, liquid oral lines for the European business, oncology, steroids, and new dosage forms. EUR 20 million (approx. INR 160+ crores) planned for plant upgrades and dossier development to meet European GMP standards for a large 6-year European contract. New product facility being set up at Baddi 1 (A 11) for serving European markets. Strategy includes adding capacity with foresight of 24 months due to plant validation timelines. Capacity expansions are spread acros

Future growth expectations in sales/revenue/volumes?

**Trade Generics:** Revenue has declined from INR 500+ crores in FY'22 to around INR 100 crores recently; business is being consolidated focusing on profitable segments with no forecast for large growth. **Domestic Formulations:** Targeting double-digit top-line growth, higher than overall Indian pharma market growth of around 8-9%. **CDMO Business:** Expecting at least 20% year-on-year growth in current export and CDMO business. Volume growth targeted in single high digits (~9% QoQ currently), with revenues dependent on volatile API prices. **Export Business:** Base branded export busin

Future growth expectations in earnings/operating earnings/profits/EPS?

**Revenue Growth**: Targeting double-digit top line growth in domestic formulations, higher than overall Indian pharma market; export business expected to grow at around 20% in next 2-3 years; CDMO business volume growth anticipated at single high digit (~9-15%). **API Business**: Losses expected to significantly reduce, targeting breakeven or minimal losses by FY '27, with revenue growth around 10-15%. **Trade Generics**: Business being consolidated due to high working capital and low profitability; future size expected to shrink but maintain profitable portions. **Margins**: CDMO margins

Current/ Expected Orderbook/ Pending Orders?

Akums Drugs & Pharmaceuticals has a significant contract in Europe valued at EUR100 million (~INR950 crores part payment received on April 9, 2025). This contract is structured as a 6-year deal, expected to generate roughly INR300-350 crores in annual revenue. The European contract marks entry into about 20 countries. The business related to this contract falls under the CDMO segment, targeting similar margins (approximately 15%-20%). For the base export branded business excluding the large European contract, the company expects high double-digit (around 20%) growth over the next 2 to 3 years.

IN US

Sale is live|00:00:00left today

Akums Drugs & Pharmaceuticals LtdQ1 FY25Pharmaceuticals & Biotechnology

Akums Drugs & Pharmaceuticals Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹609P/E: 26.6Market Cap: ₹8.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→**Trade Generics:** Revenue has declined from INR 500+ crores in FY'22 to around INR 100 crores recently; business is being consolidated focusing on profitable segments with no forecast for large growth.
→**Domestic Formulations:** Targeting double-digit top-line growth, higher than overall Indian pharma market growth of around 8-9%.
→**CDMO Business:** Expecting at least 20% year-on-year growth in current export and CDMO business. Volume growth targeted in single high digits (~9% QoQ currently), with revenues dependent on volatile API prices.
→**Export Business:** Base branded export business expected to grow at high double digits (~20%+) over next 2-3 years.
→**API Business:** Planning ~10% volume growth but revenues and profits dependent on Cephalosporin prices. Losses targeted to reduce but breakeven likely only by FY '27.
→**Capacity Planning:** Capacity utilization currently ~31-38%, with plans to enhance production for growth in oral solids and injectables.

Margin guidance

Category 2

→**Revenue Growth**: Targeting double-digit top line growth in domestic formulations, higher than overall Indian pharma market; export business expected to grow at around 20% in next 2-3 years; CDMO business volume growth anticipated at single high digit (~9-15%).
→**API Business**: Losses expected to significantly reduce, targeting breakeven or minimal losses by FY '27, with revenue growth around 10-15%.
→**Trade Generics**: Business being consolidated due to high working capital and low profitability; future size expected to shrink but maintain profitable portions.
→**Margins**: CDMO margins expected to be stable around 15-20%; overall company margin profile to improve as loss-making segments reduce losses.
→**Profitability**: EBITDA losses in API and trade generics expected to decline; overall margin and EBITDA expected to improve with strategic focus on profitable segments.
→**EPS**: With growth and margin expansion, earnings per share are expected to improve gradually aligned with business consolidation and expansion plans.

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript does not mention any current or planned fundraising through debt or equity.
→The company has a strong cash surplus of INR1,520 crores, including INR950 crores received as part payment for a European contract.
→They also have an overdraft (OD) facility on fixed deposits, indicating access to short-term credit if needed.
→Management appears focused on using available cash and possibly M&A opportunities without immediate plans for additional fundraising.
→The emphasis is on investing in capex for growth (INR300 crore planned for FY26) funded largely from internal resources.
→No explicit mention of launching new equity or debt issuance was made during the call.

Order book

→Akums Drugs & Pharmaceuticals has a significant contract in Europe valued at EUR100 million (~INR950 crores part payment received on April 9, 2025).
→This contract is structured as a 6-year deal, expected to generate roughly INR300-350 crores in annual revenue.
→The European contract marks entry into about 20 countries.
→The business related to this contract falls under the CDMO segment, targeting similar margins (approximately 15%-20%).
→For the base export branded business excluding the large European contract, the company expects high double-digit (around 20%) growth over the next 2 to 3 years.
→No specific mention of other pending orderbooks or backlog figures was made.

Capex plans

Yes

→FY '26 capex is estimated around INR 300 crores, split between maintenance and growth capex.
→Growth capex includes investments in Jammu, liquid oral lines for the European business, oncology, steroids, and new dosage forms.
→EUR 20 million (approx. INR 160+ crores) planned for plant upgrades and dossier development to meet European GMP standards for a large 6-year European contract.
→New product facility being set up at Baddi 1 (A 11) for serving European markets.
→Strategy includes adding capacity with foresight of 24 months due to plant validation timelines.
→Capacity expansions are spread across dosage forms, including injectables, oral solids, oral liquids, oncologics, and steroids.
→M&A opportunities actively explored, primarily in CDMO and export businesses, focusing on profitable and synergistic entities.
→The INR 1,000+ crores cash on books is partly earmarked but can be used for strategic investments or acquisitions.

How does Akums Drugs & Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Akums Drugs & Pharmaceuticals Ltd

Rev 3Mar 2

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Akums Drugs & Pharmaceuticals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio